Ligand Pharma (LGND) Tops Q3 EPS by 50c ; Offers Guidance
Tweet
Share
E-mailGet Alerts LGND Hot Sheet
Price: $284.91 --0%
Revenue Growth %: +33.3%
Financial Fact:
Total operating costs and expenses: 16.15M
Today's EPS Names:
DTGI, CRMT, MAYS, More
Revenue Growth %: +33.3%
Financial Fact:
Total operating costs and expenses: 16.15M
Today's EPS Names:
DTGI, CRMT, MAYS, More
Join SI Premium – FREE
Ligand Pharma (NASDAQ: LGND) reported Q3 EPS of $1.84, $0.50 better than the analyst estimate of $1.34. Revenue for the quarter came in at $51.81 million versus the consensus estimate of $40.6 million.
GUIDANCE:
Ligand Pharma sees FY2024 EPS of $5.50-$5.70, versus the consensus of $5.39. Ligand Pharma sees FY2024 revenue of $160-165 million, versus the consensus of $156.3 million.
For earnings history and earnings-related data on Ligand Pharma (LGND) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Barclays sees global expansion intact, warns against market complacency
- Commercial Metals (CMC) Tops Q3 EPS by 3c, Beats on Revenue
- Rank One Computing (ROC) Reiterated at Buy by Benchmark
Create E-mail Alert Related Categories
Earnings, GuidanceRelated Entities
Earnings, Maynard Um, Mark Zuckerberg, ARKSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
